BiotechTube

MK0869, aprepitant + Comparator: ondansetron IV

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Nausea and Vomiting

Conditions

Postoperative Nausea and Vomiting

Trial Timeline

Sep 26, 2003 → Nov 24, 2004

NCT ID
NCT00090155

About MK0869, aprepitant + Comparator: ondansetron IV

MK0869, aprepitant + Comparator: ondansetron IV is a phase 3 stage product being developed by Merck for Postoperative Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT00090155. Target conditions include Postoperative Nausea and Vomiting.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00090246Phase 3Completed
NCT00090155Phase 3Completed

Competing Products

20 competing products in Postoperative Nausea and Vomiting

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
85
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
52
Ondansetron + PalonosetronEisaiPhase 2
52
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2/3
65
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
41
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
77
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
33
EsomeprazoleAstraZenecaApproved
85
deep neuromuscular blockMerckPre-clinical
23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
52
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
85
MK0719MerckPhase 2
52
Sugammadex + NeostigmineMerckApproved
85
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85